Q3 Earnings Estimate for ODTX Issued By HC Wainwright

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) – Analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Odyssey Therapeutics in a research report issued on Thursday, August 27th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($1.13) for the quarter. HC Wainwright currently has a “Buy” rating and a $44.00 target price on the stock. The consensus estimate for Odyssey Therapeutics’ current full-year earnings is ($5.99) per share. HC Wainwright also issued estimates for Odyssey Therapeutics’ Q4 2026 earnings at ($1.19) EPS, FY2026 earnings at ($6.13) EPS, FY2027 earnings at ($5.18) EPS, FY2028 earnings at ($4.93) EPS, FY2029 earnings at ($4.68) EPS and FY2030 earnings at ($4.15) EPS.

Other research analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 20th. TD Cowen began coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued a “buy” rating for the company. Cantor Fitzgerald initiated coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “overweight” rating on the stock. JPMorgan Chase & Co. increased their price target on Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of Odyssey Therapeutics in a report on Thursday, June 18th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $35.75.

Odyssey Therapeutics Trading Down 0.1%

NASDAQ:ODTX opened at $24.50 on Monday. Odyssey Therapeutics has a 52 week low of $15.10 and a 52 week high of $28.00. The company has a market capitalization of $1.18 billion and a price-to-earnings ratio of -3.62. The business’s 50-day simple moving average is $19.92.

Odyssey Therapeutics (NASDAQ:ODTX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) EPS for the quarter.

About Odyssey Therapeutics

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.